GCL Subsidiary Epicsoft Asia Completes Acquisition of Ban Leong Technologies with Plans for Delisting

Reuters
02 Jul
GCL Subsidiary Epicsoft Asia Completes Acquisition of Ban Leong Technologies with Plans for Delisting

GCL Global Holdings Ltd.'s subsidiary, Epicsoft Asia Pte. Ltd., has successfully concluded its offer for Ban Leong Technologies Limited, acquiring approximately 96.59% of the issued shares. Following this substantial acquisition, trading of Ban Leong's shares will be suspended as the shares held in public hands have fallen below the required threshold. Epicsoft Asia plans to exercise its right for a compulsory acquisition of the remaining shares, leading to the eventual delisting of Ban Leong from the Singapore Stock Exchange. The acquisition includes significant shares tendered by Ban Leong's Managing Director, Mr. Teng Woo Boon Ronald, and his wife.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GCL Global Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9488326-en) on July 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10